SAINTE-FOY, QUEBEC--(CCNMatthews - Feb. 23, 2006) - Bioxel Pharma Inc. (TSX VEMTURE:BIP), a leading manufacturer and supplier of taxane APIs and developer of targeted oncology drugs, today announced that it has completed a 2-year, renewable paclitaxel manufacturing and supply agreement with a leading generic manufacturer in Europe. This marks the second commercial agreement signed by Bioxel for the sale of paclitaxel in Europe in the past 4 months. Paclitaxel deliveries to this new client should generate revenues of about 800,000 $ in 2006.
